CA 15-3
| Material: | 1 ml serum (Stability in serum at 4°C – 8°C: 5 days) 1 ml lithium-heparin plasma, EDTA-plasma |
| Methods: | Ligandenassays → Chemilumineszenz Mikropartikel Immunoassay (CMIA) | Reference range | < 31 U/ml |
| Indication | Therapy- and progress checks in case of mamma carcinoma (together with CEA) |
| Comment | Please also refer to: “BRCA1 and BRCA2 mutation analysis” |
| Please note | In combination with CEA, CA 15-3 is the most efficient tumor marker for mamma carcinoma. Determination of MCA does not add any further value. Various benign illnesses lead to increased CA 15-3 levels: Myomastopathy, fibro adenoma, liver and pancreas diseases, renal insufficiency, bronchial diseases, also other carcinomas such as ovarial-, bronchial-, pancreas-, liver- and stomach carcinomas. |
| Accredited | ja |
| Please also refer to: | BRCA1 and BRCA2 mutation analysis |
More Results for the letter C
- Cryofibrinogen (KRYOFI)
- Cryoglobulins (KRYO)
- Cryptococcosis (CRYPA)
- Cryptococcus neoformans, Cryptococcus gattii
- Cryptosporidia (ECRYP, MCRYP)
- CSF diagnostics (bacteriological) (LIQUORB)
- CSF diagnostics (general) (LIQUOR)
- CXCL13 (CXCL13)
- Cyclosporine A (CYCLO)
- Ciclosporine
- Cyfra 21-1 (CYFRA)
- Cystatin C (CYSTA)
- Cysteine (CYSTC)
- Cysteinyl-Dopa (5SCY)
- 5-S-cysteinyl-Dopa
- Cystine (CYST)
- Cytomegalovirus infection (CMV)